Inmode (INMD) Aktie Kurs
Inmode Kurs
Under de senaste 9 åren växte Inmode intäkterna med 36,1 % årligen och nådde 370,50 M USD. Vinst per aktie har vuxit med 83,2 % per år under de senaste 9 åren. För Inmode är nettovinstmarginal på 25,3 % ned jämfört med 46,1 % för några år sedan. Det konsensusbaserade 12-månaderskursmålet för Inmode är 19,00 USD, cirka över kursen med 34,2 %. Av 12 analytiker ger 6 köpråd — den samlade bedömningen är Köp.
Inmode aktiekurs
Hämta dessa data via Eulerpool API
100 000 anrop/mån gratis · inget kreditkort
Inmode affärsmodell och aktieanalys
Vanliga frågor om Inmode-aktien
The business model of Inmode Ltd revolves around providing innovative medical aesthetics solutions. Inmode Ltd develops and markets advanced, minimally-invasive technologies used in aesthetic and surgical procedures. Their cutting-edge platforms, such as BodyTite, FaceTite, and Morpheus8, offer solutions for skin tightening, body contouring, facial rejuvenation, and cellulite reduction. Inmode Ltd's business model centers on combining radiofrequency technology with other modalities to deliver safe, efficient, and customizable treatments for both medical professionals and patients. By continuously developing and enhancing their product portfolio, they aim to meet the growing demands of the global aesthetic market and cater to the evolving needs of healthcare practitioners.
Inmode Ltd is primarily active in the aesthetic medical device industry.
The main competitors of Inmode Ltd in the market include companies such as Cutera Inc., Cynosure Inc., Alma Lasers Ltd., and Lumenis Ltd. These companies offer similar products and services in the medical aesthetics industry, which Inmode operates in. With its innovative technologies and strong market presence, Inmode competes with these industry players to gain a larger market share and maintain its position as a leading provider of aesthetic solutions.
Inmode Ltd is a leading global provider of innovative energy-based medical aesthetic solutions. Established in 2008, the company has rapidly grown to become a trusted name in the industry. Inmode's cutting-edge technology focuses on radiofrequency-based devices, enabling physicians to deliver effective aesthetic treatments with precision and optimal patient satisfaction. Inmode Ltd is headquartered in Israel but operates worldwide, serving thousands of medical professionals and patients alike. With a commitment to continuously expanding its portfolio and investing in research and development, Inmode Ltd remains at the forefront of the medical aesthetics field, dedicated to enhancing the lives of individuals through advanced and safe technology.
Inmode Ltd, a leading provider of medical aesthetic systems, has achieved several significant milestones. The company has successfully pioneered advanced technology in minimally invasive and non-invasive procedures for aesthetic treatments. Inmode Ltd has gained worldwide recognition for its innovative platform, which includes advanced radiofrequency, laser, and pulsed light technologies. With a strong focus on research and development, they have introduced cutting-edge solutions that address a wide range of aesthetic concerns effectively and safely. Inmode Ltd continues to revolutionize the field of medical aesthetics, solidifying its position as a market leader and providing patients with exceptional treatment options.
Inmode Ltd is primarily present in various countries and regions worldwide. The company's presence extends to the United States, where it has a significant market presence. In addition, Inmode Ltd has established a strong presence in Europe, including key markets such as Germany, France, Italy, and the United Kingdom. The company also operates in the Asia-Pacific region, with a focus on countries like China and Japan. With its global reach, Inmode Ltd continues to expand its presence and deliver innovative solutions in the field of aesthetic medical technology.
Inmode Ltd represents a strong set of core values and a corporate philosophy that distinguishes the company. With a focus on innovation and cutting-edge technology, Inmode aims to provide transformative solutions in the aesthetic and medical markets. The company prides itself on quality, reliability, and versatility, ensuring that customers can trust their products and services. Inmode's commitment to research and development enables them to deliver advanced solutions, empowering healthcare professionals to enhance patient care and achieve optimal results. By prioritizing customer satisfaction and continuous improvement, Inmode Ltd strives to remain a leader in the industry.
Analytiker sätter för närvarande ett genomsnittligt riktkurs på 19,00 USD för Inmode-aktien (median: 19,00 USD), vilket innebär +34,2 % mot senaste kurs. Konsensus baseras på 12 analytikerbetyg.
12 analytiker betygsätter för närvarande Inmode-aktien: 6 rekommenderar köp, 6 behåll och 0 sälj. För 2026 väntar sig analytiker att Inmode genererar intäkter på 370,32 M USD och vinst per aktie på 1,28 USD.
Omräknat till aktuell växelkurs handlas Inmode-aktien till 12,60 EUR (14,16 USD).
Inmode-aktien (INMD) är noterad på 4 börser, bland annat: NASDAQ (INMD), Frankfurt (154.F), München (154.MU), Düsseldorf (154.DU).
Inmode Ltd is a leading company in the medical technology industry, specializing in the development and commercialization of innovative aesthetic solutions. The company offers a wide range of products and services aimed at providing patients with fast, safe, and effective treatment for aesthetic problems. Inmode specializes in four main areas: body contouring and fat reduction, skin tightening, wrinkle reduction and skin rejuvenation, and common skin problems. To address these areas, the company has developed various advanced technologies and devices available to doctors and clinics. These include: - BodyTite: A revolutionary technology that uses radiofrequency energy to melt tissue, leading to effective body contouring with minimal invasiveness. - FaceTite: A technology based on the same principles as BodyTite but specifically developed for the face and neck to tighten loose skin and reduce wrinkles. - Morpheus8: A combination of micro-needles and radiofrequency energy that stimulates collagen production and tightens the skin, reducing wrinkles and unevenness. - Votiva: A device specifically designed for women that tightens the vagina and improves sexual health. These areas and products aim to cover the entire spectrum of aesthetic needs in order to build a successful and growing customer base. Inmode also has a unique business model that goes beyond traditional sales efforts. The company has developed a strong online presence that provides potential customers with everything they need to know about the company's products and services. Inmode has also built close relationships with medical professionals around the world to ensure that their products and technologies meet the highest medical standards. In addition to providing advanced medical devices to doctors and clinics, Inmode has also developed comprehensive training and support programs to ensure that doctors and clinics are trained in the use of their technologies and can achieve the best possible results for their patients. This business model has contributed to the company's growth and success in recent years, becoming a key factor in the aesthetic medicine industry. Overall, Inmode's business model demonstrates how innovative technologies and high-quality products and services, combined with online marketing and customer relationships, can lead to a successful company.
Omsättningen för förväntad Inmode är 370,32 M USD. Denna siffra baseras på aktuella finansiella data och återspeglar företagets affärsresultat.
Nettovinsterna för förväntad Inmode är 82,11 M USD. Nettovinsterna återspeglar företagets lönsamhet efter avdrag för alla utgifter.
Kurs-vinstkvoten (P/E) för Inmode är för närvarande 11,05. P/E-talet jämför den aktuella aktiekursen med vinsten per aktie och hjälper investerare att bedöma värderingen av Inmode-aktien.
Kurs-försäljningskvoten (P/S) för Inmode är för närvarande 2,45. P/S-talet jämför börsvärdet med den årliga omsättningen och fungerar som ett värderingsmått för Inmode-aktien.
Eulerpool Quality Score för Inmode är 3/10.
ISIN för Inmode är IL0011595993. ISIN (International Securities Identification Number) är en globalt unik identifierare för värdepapper.
WKN för Inmode är A2PP3A. WKN (Wertpapierkennnummer) är ett sexsiffrigt tyskt identifieringsnummer för värdepapper.
Tickern för Inmode är INMD. Tickersymbolen används för att handla Inmode-aktier på börsen.
Inmode aktie
Inmode Jämförbar grupp
Inmode Ticker
Inmode FIGI
Alla nyckeltal och djupgående analys av Inmode
Vår aktieanalys av Inmode-aktien innehåller viktiga finansiella nyckeltal som omsättning, vinst, P/E-tal, P/S-tal, EBIT samt information om utdelningen. Dessutom granskar vi aspekter såsom aktier, börsvärde, skulder, eget kapital och skuldförbindelser hos Inmode. Om du söker mer detaljerad information om dessa ämnen erbjuder vi på våra undersidor ingående analyser: